Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 5
Submit an article Journal homepage
89
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available

Sylvain Garciaza Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, FranceCorrespondence[email protected]
View further author information
,
Guillaume Bertona Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, FranceView further author information
,
Marie-Anne Hospitala Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, FranceView further author information
,
Arnaud Guilleb Predictive Oncology Laboratory, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, FranceView further author information
,
José Adélaïdeb Predictive Oncology Laboratory, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, FranceView further author information
,
Colombe Saillarda Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, FranceView further author information
,
Yosr Hicheria Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, FranceView further author information
,
Marie-Joëlle Mozziconaccic Department of Biopathology, Institut Paoli-Calmettes, Marseille, FranceView further author information
,
Estelle Duprezd Epigenetic Factors in Normal and Malignant Hematopoiesis, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, FranceView further author information
,
Christian Réchere Department of Hematology, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France;f Université Toulouse III Paul Sabatier, Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, FranceView further author information
,
Anne-Sophie Alaryg Department of Cancer Biology, Institut Paoli-Calmettes, Marseille, FranceView further author information
,
Daniel Birnbaumb Predictive Oncology Laboratory, Marseille Cancer Research Center, INSERMUMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, FranceView further author information
&
Norbert Veya Department of Hematology, Institut Paoli-Calmettes, INSERM UMR 1068, CNRS UMR725, CNRS, Aix-Marseille University, Marseille, FranceView further author information
 show all
Pages 700-703 | Received 19 Jun 2023, Accepted 26 Jan 2024, Published online: 08 Feb 2024

References

  • Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–266. doi:10.1056/NEJMoa041974
  • Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 ELN Recommendations from an International Expert Panel. Blood. 2022;140(12):1345–1377. doi:10.1182/blood.2022016867
  • Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi:10.1056/NEJMoa1516192
  • Gale RE, Lamb K, Allen C, et al. Simpson’s paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015;33(18):2072–2083. doi:10.1200/JCO.2014.59.2022
  • Chou W-C, Lei W-C, Ko B-S, et al. The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia. 2011;25(2):246–253. doi:10.1038/leu.2010.267
  • Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089. doi:10.1056/NEJMoa1112304
  • Duchmann M, Micol J-B, Duployez N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021;137(20):2827–2837. doi:10.1182/blood.2020010165
  • DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732–736. doi:10.1002/ajh.24072
  • Dunlap JB, Leonard J, Rosenberg M, et al. The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML. Am J Hematol. 2019;94(8):913–920. doi:10.1002/ajh.25517
  • Oñate G, Bataller A, Garrido A, et al. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv. 2022;6(3):882–890. doi:10.1182/bloodadvances.2020004136
  • Wang R, Gao X, Yu L. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis. BMC Cancer. 2019;19(1):389. doi:10.1186/s12885-019-5602-8
  • Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228. doi:10.1182/blood.2022015850
  • Garciaz S, N'guyen Dasi L, Finetti P, et al. Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 ­mutation. Clin Epigenet. 2019;11(1):141. doi:10.1186/s13148-019-0738-6
  • Eisfeld A-K, Kohlschmidt J, Mims A, et al. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years. Leukemia. 2020;34(12):3215–3227. doi:10.1038/s41375-020-0872-3
  • Wakita S, Marumo A, Morita K, et al. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. Cancer Sci. 2023;114(4):1297–1308. doi:10.1111/cas.15720
  • Blau O, Behrenbeck F, Bayanova M, et al. Characteristics of DNMT3A-R882 mutation in AML. Blood. 2018;132(Suppl. 1):5263. doi:10.1182/blood-2018-99-116652
  • Kumar D, Mehta A, Panigrahi MK, et al. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in coexistent with NPM1 and FLT3 mutations. Hematol Oncol Stem Cell Ther. 2018;11(2):82–89. doi:10.1016/j.hemonc.2017.09.004

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.